Isabella Heuser

Isabella Heuser

Auto-generated profile, based on publicly available information

Isabella Heuser

Charité - Universitaetsmedizin Berlin, Department of Psychiatry and Neurosciences, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
JHJulian Hellmann-Regen
Julian Hellmann-Regen
VCVera Clemens
Vera Clemens
MGMichael Grözinger
Michael Grözinger
JKJohannes Kornhuber
Johannes Kornhuber
ARAndreas Reif
Andreas Reif
IHIsabella Heuser
Isabella Heuser
Major depressive disorder (MDD) is an important cause of disability worldwide.1 Insufficient response rates, persistent residual symptoms, frequent relapse or recurrence of symptoms constitute unsatisfactory outcomes of conventional antidepressant treatments. Response rates for an initial treatment are estimated at roughly 50% with a substantial proportion lacking full remission even following various switching and augmentation strategies of the antidepressant regimen.2

10 October 2017 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
LFLutz FROELICH
Lutz FROELICH
OPOliver Peters
Oliver Peters
PLPiotr Lewczuk
Piotr Lewczuk
OGOliver Gruber
Oliver Gruber
STStefan J Teipel
Stefan J Teipel
JKJohannes Konrhuber
Johannes Konrhuber
The progression of mild cognitive impairment (MCI) to Alzheimer’s disease (AD) dementia can be predicted by cognitive, neuroimaging, and cerebrospinal fluid (CSF) markers. Since most biomarkers reveal complementary information, a combination of biomarkers may increase the predictive power. We investigated which combination of the Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR)-sum-of-boxes, the word list delayed free recall from the Consortium to Establish a Registry of Dementia (CERAD) test battery, hippocampal volume (HCV), amyloid-beta1–42 (Aβ42), amyloid-beta1–40 (Aβ40) levels, the ratio of Aβ42/Aβ40, phosphorylated tau, and total tau (t-Tau) levels in the CSF best predicted a short-term conversion from MCI to AD dementia. We used 115 complete datasets from MCI patients of the “Dementia Competence Network”, a German multicenter cohort study with annual follow-up up to 3 years. MCI was broadly defined to include amnestic and nonamnestic syndromes. Variables known to predict progression in MCI patients were selected a priori. Nine individual predictors were compared by receiver operating characteristic (ROC) curve analysis. ROC curves of the five best two-, three-, and four-parameter combinations were analyzed for significant superiority by a bootstrapping wrapper around a support vector machine with linear kernel. The incremental value of combinations was tested for statistical significance by comparing the specificities of the different classifiers at a given sensitivity of 85%. Out of 115 subjects, 28 (24.3%) with MCI progressed to AD dementia within a mean follow-up period of 25.5 months. At baseline, MCI-AD patients were no different from stable MCI in age and gender distribution, but had lower educational attainment. All single biomarkers were significantly different between the two groups at baseline. ROC curves of the individual predictors gave areas under the curve (AUC) between 0.66 and 0.77, and all single predictors were statistically superior to Aβ40. The AUC of the two-parameter combinations ranged from 0.77 to 0.81. The three-parameter combinations ranged from AUC 0.80–0.83, and the four-parameter combination from AUC 0.81–0.82. None of the predictor combinations was significantly superior to the two best single predictors (HCV and t-Tau). When maximizing the AUC differences by fixing sensitivity at 85%, the two- to four-parameter combinations were superior to HCV alone. A combination of two biomarkers of neurodegeneration (e.g., HCV and t-Tau) is not superior over the single parameters in identifying patients with MCI who are most likely to progress to AD dementia, although there is a gradual increase in the statistical measures across increasing biomarker combinations. This may have implications for clinical diagnosis and for selecting subjects for participation in clinical trials.

9 February 2010 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
SZSara Zeugmann
Sara Zeugmann
AQArnim Quante
Arnim Quante
IHIsabella Heuser
Isabella Heuser
Ralf SchwarzerRalf Schwarzer
Ralf Schwarzer
IAIon Anghelescu
Ion Anghelescu
Chronic subclinical inflammation may be associated with the metabolic syndrome as well as with depression. We examined the impact of the metabolic syndrome on concentrations of inflammatory biomarkers in major depression. Data for 70 inpatients with major depressive disorder (diagnosed according to ICD-10 and DSM-IV), and with or without the metabolic syndrome, were assessed 4 to 5 weeks after admission to the clinic of the Department of Psychiatry, Charité-University Medicine, Berlin, between 2005 and 2007. The metabolic syndrome was defined according to the criteria of the International Diabetes Federation (2005). Immunologic biomarkers assessed included adiponectin, resistin, serum amyloid A (SAA), C-reactive protein (CRP), fibrinogen, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), soluble E-selectin, and CD40 ligand (CD40L). Severity of depression was measured with the 17-item Hamilton Depression Rating Scale. After regressional correction for confounding variables and covariates, a 2-factorial analysis of variance (metabolic syndrome x time) revealed that the metabolic syndrome's presence affected adiponectin (F(43,1) = 5.56; P < .05) and IL-6 levels (F(25,1) = 6.80; P < .05) significantly. There was also a trend for effects on fibrinogen levels (F(47,1) = 3.66; P = .06). This is the first study to evaluate the putative additive effect of the metabolic syndrome on a panel of 9 inflammatory biomarkers in depression. Our findings support an additive effect on some (adiponectin, IL-6, and trendwise for fibrinogen) markers. Patients with the metabolic syndrome and major depression are at higher risk for more frequent and more severe cardiovascular side effects than their counterparts without the metabolic syndrome.

1 July 2012 in Psychology & Health
Verified
Journal Article
Closed access
AEAndrea W.M. Evers
Andrea W.M. Evers
VKVerena Klusmann
Verena Klusmann
JZJochen P. Ziegelmann
Jochen P. Ziegelmann
Ralf SchwarzerRalf Schwarzer
Ralf Schwarzer
IHIsabella Heuser
Isabella Heuser
Objective: This study investigated the role of coping plans and the use of selection, optimisation and compensation (SOC) strategies within an experimental evaluation of a 26-week physical exercise intervention. Methods: Older women (N = 86, M age = 73.7 years) were randomly assigned to a telephone-assisted or a self-administered coping planning intervention after 6 weeks’ participation in an exercise programme. The number of different coping plans formulated, exercise-specific SOC strategy use and their interaction were used to predict objectively measured long-term adherence to the intervention. Results: The number of coping plans formulated (β = 0.28) and goal-pursuit strategies reported (sum score of optimisation and compensation strategies, β = 0.39) predicted adherence to the exercise programme over 20 weeks. The predictive strength of coping plans increased with decreasing numbers of goal-pursuit strategies (β = −0.21). Women supported via telephone reported significantly more coping plans than did women in the self-administered coping planning group, F(1,80) = 9.47, p = 0.003. Conclusion: Coping plans have a buffering effect on adherence levels when use of SOC strategies is low. Older women's adherence to physical activities may be improved if they are given direct support in generating coping plans involving strategies of selection, optimisation and compensation.

21 September 2018 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
VCVera Clemens
Vera Clemens
FRFrancesca Regen
Francesca Regen
NBNathalie Le Bret
Nathalie Le Bret
IHIsabella Heuser
Isabella Heuser
JHJulian Hellmann-Regen
Julian Hellmann-Regen
Minocycline is a lipophilic tetracycline of increasing appeal in neuroscience as it inhibits microglial activation, a mechanism involved in numerous neuropsychiatric disorders. Own data point towards retinoid-mediated effects of minocycline in murine brain and skin, and towards a vicious cycle of neuroinflammation which is driven by microglial activation-induced breakdown of local retinoids such as retinoic acid (RA). We therefore sought to study minocycline’s anti-inflammatory effects on human microglial-like monocyte-derived cells in the context of retinoid signaling. As hypothesized, minocycline exposure resulted in a substantial increase of RA levels in the human monocytic cell line THP-1. While pro-inflammatory stimulation with lipopolysaccharides resulted in increased tryptophane-degrading indoleamine-2,3-dioxygenase IDO-expression and TNF-α levels in primary human monocyte-derived microglial-like cells, this effect was attenuated by minocycline only in the presence of retinoids. The anti-inflammatory effects of minocycline on TNF-α expression were completely abolished by a pharmacological blockage of retinoic acid receptors (RARs) using BMS-493 and unaffected by selectively blocking retinoid-X-receptors using UVI-3003. Our data indicate for the first time a RA-dependent, anti-inflammatory effect for minocycline in human microglial-like cells via inhibition of local RA turnover. The RA-dependent mode of action for minocycline appears to be predominantly mediated through RAR-signaling.

1 September 2014 in Journal of Affective Disorders
Verified
Journal Article
Closed access
JKJan Philipp Klein
Jan Philipp Klein
BBBenjamin Becker
Benjamin Becker
RHRene Hurlemann
Rene Hurlemann
CSChristina Scheibe
Christina Scheibe
MCMichael Colla
Michael Colla
IHIsabella Heuser
Isabella Heuser